ERBB2 and breast carcinoma: On the other hand, a post hoc multivariate analysis in the Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (APHINITY) Trial [40], including 4804 patients with a median follow-up of 6.2 years, showed that statin use was not associated with invasive disease-free survival (IDFS) (HR, 1.11; 95% CI, 0.80–1.52), distant relapse-free interval (DRFI) (HR, 1.21; 95% CI, 0.81–1.81), or overall survival (OS) (HR, 1.16; 95% CI, 0.78–1.73).